(0.33%) 5 117.01 points
(0.33%) 38 365 points
(0.38%) 15 988 points
(-0.98%) $83.03
(5.56%) $2.03
(0.34%) $2 355.20
(0.49%) $27.67
(4.07%) $959.65
(-0.26%) $0.932
(-0.41%) $10.98
(-0.57%) $0.796
(1.69%) $93.43
Live Chart Being Loaded With Signals
ZIOPHARM Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing a portfolio of immuno-oncology therapies to treat patients with cancer...
Stats | |
---|---|
本日の出来高 | 2.13M |
平均出来高 | 2.36M |
時価総額 | 208.12M |
EPS | $0 ( 2022-02-23 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -2.07 |
ATR14 | $0.104 (12.01%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2021-12-22 | De Groot Eleanor | Sell | 20 132 | Common Stock |
2021-03-04 | Thistle Mary | Buy | 150 000 | Stock Option (right to buy) |
2021-03-04 | Thistle Mary | Buy | 37 500 | Stock Option (right to buy) |
2021-03-04 | Thistle Mary | Buy | 5 000 | Common Stock |
2021-03-04 | Buchi J Kevin | Buy | 31 250 | Stock Option (right to buy) |
INSIDER POWER |
---|
0.00 |
Last 95 transactions |
Buy: 4 516 054 | Sell: 1 683 458 |
ボリューム 相関
ZIOPHARM Oncology Inc 相関
10 最も負の相関 | |
---|---|
ITAQU | -0.963 |
MCAA | -0.954 |
OPRA | -0.945 |
RCEL | -0.941 |
COCO | -0.939 |
BRLI | -0.938 |
ARYD | -0.937 |
APTM | -0.935 |
SLAM | -0.935 |
TZPS | -0.934 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
ZIOPHARM Oncology Inc 相関 - 通貨/商品
ZIOPHARM Oncology Inc 財務諸表
Annual | 2020 |
収益: | $0.00 |
総利益: | $0.00 (0.00 %) |
EPS: | $-0.380 |
FY | 2020 |
収益: | $0.00 |
総利益: | $0.00 (0.00 %) |
EPS: | $-0.380 |
FY | 2019 |
収益: | $0.00 |
総利益: | $0.00 (0.00 %) |
EPS: | $-0.700 |
FY | 2018 |
収益: | $146 000 |
総利益: | $0.00 (0.00 %) |
EPS: | $-0.370 |
Financial Reports:
No articles found.
ZIOPHARM Oncology Inc
ZIOPHARM Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing a portfolio of immuno-oncology therapies to treat patients with cancer. The company develops Sleeping Beauty platform, which is based on the non-viral genetic engineering of immune cells using a transposon/transposase system to engineer T-cells outside of the body for infusion; and Controlled IL-12 to stimulate expression of interleukin 12 or IL-12, a master regular of the immune system, in a controlled manner to focus the patient's immune system to attack cancer cells. Its product candidates include T cell receptor + T therapies to target solid tumors; chimeric antigen receptor + T cell therapies targeting CD19 for hematologic malignancies; and Ad-RTS-hIL-12 plus veledimex, a gene delivery system to regulate production of IL-12 to treat patients with recurrent glioblastoma multiforme in adults. The company has a license agreement with PGEN Therapeutics, Inc.; research and development agreement with The University of Texas MD Anderson Cancer Center; a patent license agreement with the National Cancer Institute; and a cooperative research and development agreement with the National Cancer Institute. ZIOPHARM Oncology, Inc. is headquartered in Boston, Massachusetts.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。